We noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Chemotherapy-induced peripheral neurotoxicity
- Risk of CIPN
- Drug induced impairment
- Open issues (1)
- No effecttive blood-nervous system barrier
- CIPN or CIPNs?
- Platinum-derived drugs
- Clinical features of platinum-derived drugs
- Platinum-derived drugs: sensory impairment
- Thalidomide (1)
- Thalidomide (2)
- Metabolic products of thalidomide
- New IMIDs: lenalidomide
- Antitubulin agents: taxanes
- Clinical features of taxanes
- Laboratory clinical features of taxanes
- Antitubulin agents: epothilons
- Antitubulin agents: vinca alkaloids
- Clinical features of antitubulin agents
- Laboratory clinical features of antitubulin agents
- Antitubulin agents: sensory-motor impairment
- Proteasome inhibitors
- Proteasome inhibitors: sensory impairment
- Open issues (2)
- Outcome measures
- Open issues (3)
- New drugs: brentuximab vedotin
- New drugs: immune checkpoint inhibitors
- Open issues (4)
- Putative biomarkers (1)
- CIPN in the era of pharmacogenomics
- CIPN-associated polymorphisms
- CIPN-associated genes
- Problems with pharmacogenetic studies
- A predisposing factor for CIPN
- Putative biomarkers (2)
- NGF as a biomarker
- Neurofilament light chains as a biomarker
- Lecure summary
- Toxic neuropathy consortium
- Disclosures
Topics Covered
- Clinical features of CIPN induced by different chemotherapy drugs
- Potential CIPN biomarkers
- Assessment of CIPN
- Chemotherapy drugs and their properties
- New drugs and current research
Talk Citation
Cavaletti, G. (2020, February 27). Chemotherapy-induced peripheral neurotoxicity [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 6, 2024, from https://doi.org/10.69645/EGQR7244.Export Citation (RIS)
Publication History
Financial Disclosures
- Commercial/Financial matters disclosed are: Dr. Cavaletti declares personal financial interests as a consultant for Toray, Disarm, Helsinn and Seattle Genetics, and is on the clinical trial advisory board of Pledpharma and Mundipharma. Furthermore, Dr. Cavaletti also declares institutional financial interests holding institutional research grants from Kedrion, Chiesi and Mundipharma. Dr. Cavaletti is also a board member for Peripheral Nerve Society, as well as being the chair for the Toxic Neuropathy Consortium.
A selection of talks on Oncology
Transcript
Please wait while the transcript is being prepared...
0:00
My name is we Guido Cavaletti.
I'm a neurologists working at University of Milano-Bicocca in Monza, Italy.
I am the Head of the Experimental Neurology Unit,
where we combine clinical and preclinical assessment
of chemotherapy-induced peripheral neurotoxicity,
in order to better understand which are the reasons why
a patient can develop this kind of very severe side effect,
and which might be the possible prevention strategy to limit the severity of the disease.
0:34
Chemotherapy-induced peripheral neurotoxicity is a very complex topic.
One of the main reasons why it is complex is that,
several players are involved around the same problem.
The patient who is faced with cancer and
needs to be treated with drugs that can be neurotoxic.
The oncologist who is in charge of the treatment of
the patient and of the selection of the best treatment schedule,
and is well aware that he can be the reason for the development of side effects,
and the neurologists who are in charge of monitoring and
assessing the severity of the neurotoxic side effect.
The interaction between all these people can be
difficult from different contexts and for different reasons.
Patients are required to be treated with the best treatment available,
and then to under-report the occurrence of mild side effects.
Oncologists need to follow effective protocols,
and are well aware that the only way to limit the severity of
CIPN is to reduce the drug or even withdraw from the treatment.
Neurologists are often faced with the problem once neuropathy is already clearly evident,
and in most cases is too late to really
intervene with some effective procedure or treatment.
So for all these reasons,
this is a clear example of
a multi-disciplinary clinical need that
still needs to be addressed in much more deep detail.